EMEA-001157-PIP01-11-M02
Key facts
Active substance |
Caplacizumab
|
Therapeutic area |
Haematology-Hemostaseology
|
Decision number |
P/0294/2018
|
PIP number |
EMEA-001157-PIP01-11-M02
|
Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
Condition(s) / indication(s) |
Treatment of thrombotic thrombocytopenic purpura (TTP)
|
Route(s) of administration |
|
Contact for public enquiries |
Ablynx NV
E-mail: bernard.delaey@ablynx.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-001157-PIP01-11-M02
|
Compliance opinion date |
23/08/2019
|
Compliance outcome |
positive
|